Help Support EcoWatch
The best of EcoWatch, right in your inbox. Sign up for our email newsletter!
By Stuart Braun
1.3 billion plastic bottles are sold daily around the world. And that's just the tip of the fossil-based plastic iceberg. Plastic preserves our food. It's in the nylon and polyester we wear, and it protects medical staff from the coronavirus.
Petroleum-based plastics dominate the market because they're durable, light-weight and cheap, but most of them can't be recycled or reused.
A raft of new bioplastic innovations is starting to catch up, though. And, unlike unsustainable fossil fuels, they are derived from renewable sources.
While bioplastics have the same molecular structure as petroleum-based plastics, which take hundreds of years to decompose, research shows that biomass-based polymers are also more likely to biodegrade and break down, including in industrial compost facilities. Bioplastic proponents believe they are key to making plastic part of a circular economy.
Here's a look at five ingredients that could make bioplastics competitive with traditional plastics.
1. Olive Pits
Countries that produce a lot of olive oil have a byproduct that can be used for plastic: olive pits. A Turkish startup called Biolive began creating a range of began creating a range of bioplastic granules created from olive seeds that result in bio-based, partially biodegradable products that can decompose in a year.
The active ingredient oleuropein found in olive seeds is an antioxidant that extends the life of the bioplastic while also hastening composting of the material into fertilizer within a year.
And since Biolive's granules act like fossil fuel-based plastics, plastic producers can simply substitute the conventional granules without disrupting the production cycle for industrial products and food packaging.
Biolive claims that by utilizing olive oil waste, production costs are reduced by up to 90% in relation to some existing bioplastics. This is important says founder Duygu Yilmaz, since starch-based bioplastics made from corn are often more expensive than petroleum-based plastics are therefore not a viable alternative.
In 2019, award-winning Biolive was chosen to represent Turkey at the United Nations Development Programme.
2. Sunflower Hulls
Like olive seeds, the husks of sunflower seeds used for oil production is a waste product also being used to created bioplastics. And luckily, they're in near endless supply.
The German start-up Golden Compound has created a unique Sustainable Sunflower Plastic Compound bioplastic – referred to as S²PC. It's reinforced with sunflower hulls, which they claim are 100% recyclable.
The S²PC bioplastic is being moulded into everything from office furniture to recyclable transport and storage boxes and crates.
Golden Compound also produces a "green" bioplastic that is 100% biodegradable, GMO-free and can be fully composted at home. Products include award-winning, world-first biodegradable coffee capsules, plant pots and coffee mugs.
The German start-up attributes the success of its bioplastics to performance. "In the end, the only reason people will be willing to switch, is if it works," Marcel Dartée, General Manager at Golden Compound, told the Plastic Today trade publication.
3. Fish Waste and Algae
The growing attempt to transform organic waste into plastic now includes fish processing refuse.
A UK initiative called MarinaTex is using fish skin and scales – 500,000 tons of which are generated annually in the UK alone – bound with red algae to make a compostable plastic alternative that can replace single-use plastics such as bakery bags and sandwich packs.
MarinaTex claims the biopolymer creates stronger packaging than a conventional plastic bag — flying in the face of perceptions that bioplastics lack strength and durability.
Lucy Hughes, who created the product in her final year at the University of Sussex, says MarinaTex's flexibility, strength and pliability was inspired by actual fish skin and scales.
"It kind of struck me that nature can make so much from so little, so why do we need to have hundreds of man-made polymers when nature has so many already available," she told the World Economic Forum in November.
MarinaTex, which won the 2019 James Dyson Award worth €35,000, describes its product as home compostable and says it can break down within four to six weeks.
Meet the woman turning fish waste into an alternative to single-use plastic. Lucy Hughes, a student from the UK's… https://t.co/uyVd76HdaT— DW Europe (@DW Europe)1573750505.0
4. Plant Sugars
While PET is one of the most recyclable fossil-based plastics it takes hundreds of years to decompose. In response, Amsterdam-based Avantium has created a revolutionary "YXY" plants-to-plastics technology that converts plant-based sugars into a new biodegradable packaging material, polyethylene furanoate or PEF.
A trial of PEF biodegradability in the natural environment is showing promising signs.
"PEF degrades much faster than PET under industrial composting conditions," Caroline van Reedt Dortland, Director Communications at Avantium, told DW. Degrading in 250-400 days as opposed to 300-500 years is significant.
It is used as a textile, film, and has the potential to become a major player in the packaging of soft drinks, water, alcoholic beverages and fruit juices, having already collaborated with the likes of Carlsberg to create a "100% bio-based" beer bottle.
According to Hasso Pogrell of European Bioplastics, it's even possible to " recycle PEF together with PET, and it makes the PET recyclate perform even better than the original PET."
Gadget blog Gizmodo wrote back in 2015 about resilient and biodegradable fungal mycelia-based materials which, unlike oil-based plastic, "create no toxic byproducts."
One emerging brand utilizing fungi is Reishi, a sustainable, fine mycelium leather substitute created from a woven cellular microstructure derived from mushrooms. By emulating the collagen structure of animal leathers, Reishi fine mycelium is both sustainable and versatile.
Reishi creator MycoWorks has taken the water-resistant biomaterial to the next level, promising the performance, quality and aesthetics of leather or synthetic plastic materials, but with a negative carbon footprint.
Already utilized by a selection of European luxury and footwear brands, in late 2019 $17 million (€18 million) financing was raised to help deliver commercially viable non-plastic, non-animal Reishi materials to the market.
In terms of limiting fossil-based plastic consumption, the biomaterial aims to outperform existing "vegan leathers" that are created with unsustainable plastics.
Imagine a world where we are using sustainable biomaterials #Mycoworks #Lingrove https://t.co/fA6UIyThr4 https://t.co/m4OicryCBx— IndieBio (@IndieBio)1527557108.0
Reposted with permission from Deutsche Welle.
- 4 Eco-Friendly Drinking Straw Alternatives So You Can Skip Plastic ... ›
- This Company Has a Genius Solution for Discarded Avocado Pits ... ›
- 20 Facts About Our Plastic-Packed Planet and 9 Ways to Help ... ›
- Plastic Bottle Made From Plants Degrades in Just One Year - EcoWatch ›
EcoWatch Daily Newsletter
On Monday and Tuesday of the week that President Donald Trump held his first rally since March in Tulsa, Oklahoma, the county reported 76 and 96 new coronavirus cases respectively, according to POLITICO. This week, the county broke its new case record Monday with 261 cases and reported a further 206 cases on Tuesday. Now, Tulsa's top public health official thinks the rally and counterprotest "likely contributed" to the surge.
- No Social Distancing or Mask Requirement at Trump's Mt ... ›
- Trump Plans to End Federal Funding for COVID-19 Testing Sites ... ›
- Attendees at Trump's First Rally Since March Can't Sue if They Get ... ›
Rainforests are an important defense against climate change because they absorb carbon. But many are being destroyed on a massive scale.
- Brazil's Amazon Rainforest Is the Wild West for Illegal Gold Miners ... ›
- Trump Moves to Open 16.7 Million Acre Alaskan Rainforest to ... ›
- Amazon Rainforest Reaches Point of No Return - EcoWatch ›
As we look for advanced technology to replace our dependence on fossil fuels and to rid the oceans of plastic, one solution to the climate crisis might simply be found in rocks. New research found that dispersing rock dust over farmland could suck billions of tons of carbon dioxide from the air every year, according to the first detailed large scale analysis of the technique, as The Guardian reported.
- California Startup Opus 12 Recycles Carbon Dioxide - EcoWatch ›
- UK Biomass Plant Starts Groundbreaking Carbon Capture Project ... ›
- 8 Ways to Sequester Carbon to Avoid Climate Catastrophe - EcoWatch ›
By Tim Radford
German scientists now know why so many fish are so vulnerable to ever-warming oceans. Global heating imposes a harsh cost at the most critical time of all: the moment of spawning.
Nearing the Brink<p>Since <a href="https://climatenewsnetwork.net/abundant-fish-need-cool-seas-and-protection/" target="_blank">fish in the temperate zones already experience a wide variation</a> in seasonal water temperatures, it hasn't been obvious why species such as <a href="https://climatenewsnetwork.net/sardines-swim-into-northern-waters-to-keep-cool/" target="_blank">cod have shifted nearer the Arctic, and sardines have migrated to the North Sea</a>.</p><p>But <a href="https://climatenewsnetwork.net/ocean-warming-spurs-marine-life-to-rapid-migration/" target="_blank">marine creatures are on the move</a>, and although there are other factors at work, including overfishing and <a href="https://climatenewsnetwork.net/fish-cant-smell-well-in-more-acidic-seas/" target="_blank">the increasingly alarming changes in ocean chemistry</a>, thanks to ever-higher levels of dissolved carbon dioxide, temperature change is part of the problem.</p><p>The latest answer, Dr Dahlke and his colleagues report in the journal <a href="https://science.sciencemag.org/cgi/doi/10.1126/science.aaz3658" target="_blank">Science</a>, is that many fish may already be living near the limits of their thermal tolerance.</p><p>The temperature safety margins during the moments of spawning and embryo might be very precise, and over hundreds of thousands of years of evolution, marine and freshwater species have worked out just what is best for the next generation. Rapid global warming upsets this equilibrium.</p>
By Sherry H-Y. Chou, Aarti Sarwal and Neha S. Dangayach
The patient in the case report (let's call him Tom) was 54 and in good health. For two days in May, he felt unwell and was too weak to get out of bed. When his family finally brought him to the hospital, doctors found that he had a fever and signs of a severe infection, or sepsis. He tested positive for SARS-CoV-2, the virus that causes COVID-19 infection. In addition to symptoms of COVID-19, he was also too weak to move his legs.
When a neurologist examined him, Tom was diagnosed with Guillain-Barre Syndrome, an autoimmune disease that causes abnormal sensation and weakness due to delays in sending signals through the nerves. Usually reversible, in severe cases it can cause prolonged paralysis involving breathing muscles, require ventilator support and sometimes leave permanent neurological deficits. Early recognition by expert neurologists is key to proper treatment.
We are neurologists specializing in intensive care and leading studies related to neurological complications from COVID-19. Given the occurrence of Guillain-Barre Syndrome in prior pandemics with other corona viruses like SARS and MERS, we are investigating a possible link between Guillain-Barre Syndrome and COVID-19 and tracking published reports to see if there is any link between Guillain-Barre Syndrome and COVID-19.
Some patients may not seek timely medical care for neurological symptoms like prolonged headache, vision loss and new muscle weakness due to fear of getting exposed to virus in the emergency setting. People need to know that medical facilities have taken full precautions to protect patients. Seeking timely medical evaluation for neurological symptoms can help treat many of these diseases.
What Is Guillain-Barre Syndrome?
Guillain-Barre syndrome occurs when the body's own immune system attacks and injures the nerves outside of the spinal cord or brain – the peripheral nervous system. Most commonly, the injury involves the protective sheath, or myelin, that wraps nerves and is essential to nerve function.
Without the myelin sheath, signals that go through a nerve are slowed or lost, which causes the nerve to malfunction.
To diagnose Guillain-Barre Syndrome, neurologists perform a detailed neurological exam. Due to the nerve injury, patients often may have loss of reflexes on examination. Doctors often need to perform a lumbar puncture, otherwise known as spinal tap, to sample spinal fluid and look for signs of inflammation and abnormal antibodies.
Studies have shown that giving patients an infusion of antibodies derived from donated blood or plasma exchange – a process that cleans patients' blood of harmful antibodies - can speed up recovery. A very small subset of patients may need these therapies long-term.
The majority of Guillain-Barre Syndrome patients improve within a few weeks and eventually can make a full recovery. However, some patients with Guillain-Barre Syndrome have lingering symptoms including weakness and abnormal sensations in arms and/or legs; rarely patients may be bedridden or disabled long-term.
Guillain-Barre Syndrome and Pandemics
As the COVID-19 pandemic sweeps across the globe, many neurologic specialists have been on the lookout for potentially serious nervous system complications such as Guillain-Barre Syndrome.
Though Guillain-Barre Syndrome is rare, it is well known to emerge following bacterial infections, such as Campylobacter jejuni, a common cause of food poisoning, and a multitude of viral infections including the flu virus, Zika virus and other coronaviruses.
Studies showed an increase in Guillain-Barre Syndrome cases following the 2009 H1N1 flu pandemic, suggesting a possible connection. The presumed cause for this link is that the body's own immune response to fight the infection turns on itself and attacks the peripheral nerves. This is called an "autoimmune" condition. When a pandemic affects as many people as our current COVID-19 crisis, even a rare complication can become a significant public health problem. That is especially true for one that causes neurological dysfunction where the recovery takes a long time and may be incomplete.
Though there is clear clinical suspicion that COVID-19 can lead to Guillain-Barre Syndrome, many important questions remain. What are the chances that someone gets Guillain-Barre Syndrome during or following a COVID-19 infection? Does Guillain-Barre Syndrome happen more often in those who have been infected with COVID-19 compared to other types of infections, such as the flu?
The only way to get answers is through a prospective study where doctors perform systematic surveillance and collect data on a large group of patients. There are ongoing large research consortia hard at work to figure out answers to these questions.
Understanding the Association Between COVID-19 and Guillain-Barre Syndrome
While large research studies are underway, overall it appears that Guillain-Barre Syndrome is a rare but serious phenomenon possibly linked to COVID-19. Given that more than 10.7 million cases have been reported for COVID-19, there have been 10 reported cases of COVID-19 patients with Guillain-Barre Syndrome so far – only two reported cases in the U.S., five in Italy, two cases in Iran and one from Wuhan, China.
It is certainly possible that there are other cases that have not been reported. The Global Consortium Study of Neurological Dysfunctions in COVID-19 is actively underway to find out how often neurological problems like Guillain-Barre Syndrome is seen in hospitalized COVID-19 patients. Also, just because Guillain-Barre Syndrome occurs in a patient diagnosed with COVID-19, that does not imply that it was caused by the virus; this still may be a coincident occurrence. More research is needed to understand how the two events are related.
Due to the pandemic and infection-containment considerations, diagnostic tests, such as a nerve conduction study that used to be routine for patients with suspected Guillain-Barre Syndrome, are more difficult to do. In both U.S. cases, the initial diagnosis and treatment were all based on clinical examination by a neurological experts rather than any tests. Both patients survived but with significant residual weakness at the time these case reports came out, but that is not uncommon for Guillain-Barre Syndrome patients. The road to recovery may sometimes be long, but many patients can make a full recovery with time.
Though the reported cases of Guillain-Barre Syndrome so far all have severe symptoms, this is not uncommon in a pandemic situation where the less sick patients may stay home and not present for medical care for fear of being exposed to the virus. This, plus the limited COVID-19 testing capability across the U.S., may skew our current detection of Guillain-Barre Syndrome cases toward the sicker patients who have to go to a hospital. In general, the majority of Guillain-Barre Syndrome patients do recover, given enough time. We do not yet know whether this is true for COVID-19-related cases at this stage of the pandemic. We and colleagues around the world are working around the clock to find answers to these critical questions.
Sherry H-Y. Chou is an Associate Professor of Critical Care Medicine, Neurology, and Neurosurgery, University of Pittsburgh.
Aarti Sarwal is an Associate Professor, Neurology, Wake Forest University.
Neha S. Dangayach is an Assistant Professor of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai.
Disclosure statement: Sherry H-Y. Chou receives funding from The University of Pittsburgh Clinical Translational Science Institute (CTSI), the National Institute of Health, and the University of Pittsburgh School of Medicine Dean's Faculty Advancement Award. Sherry H-Y. Chou is a member of Board of Directors for the Neurocritical Care Society. Neha S. Dangayach receives funding from the Bee Foundation, the Friedman Brain Institute, the Neurocritical Care Society, InCHIP-UConn Center for mHealth and Social Media Seed Grant. She is faculty for emcrit.org and for AiSinai. Aarti Sarwal does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Reposted with permission from The Conversation.